Searched for
GENERIC DRUG USER FEE
Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gelAlembic Pharmaceuticals has secured final USFDA approval for its generic Dapsone gel, a topical treatment for acne vulgaris. This approval,...- 'They will watch a 3hr podcast if...': Ankur Warikoo says Gen Z doesn't have a short attention span, just a faster rejection spanEntrepreneur Ankur Warikoo has ignited a debate on social media, asserting that Gen Z possesses a 'faster rejection span' rather than a sho...
- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
- Manipur CM says drug trafficking routes have changed after 2023 crisis, largely diverting through MizoramManipur Chief Minister Yumnam Khemchand Singh revealed that drug trafficking routes have shifted significantly post-2023 crisis, largely di...
- 'It costs Rs 1.5 lakh a month just to exist': Indian-origin man asks if Rs 4.6 lakh is enough in BengaluruAn Indian-origin man's detailed monthly budget for relocating to North Bengaluru after 15 years in the US has sparked a lively Reddit discu...
- Vande Mataram not just song, but mantra for reconstruction of India: Union Home Minister Amit ShahUnion Home Minister Amit Shah declared 'Vande Mataram' a 'mantra for India's reconstruction' while honoring Bankim Chandra Chattopadhyay. S...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Alembic Pharma gets USFDA nod for generic influenza treatment drugAlembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. Th...
- 'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...
- Lupin gets USFDA tentative approval for prostate cancer treatment drugIndian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatm...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Alembic Pharma gets tentative nod from USFDA for generic cancer drugAlembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step fo...
- US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisitionThe U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
Load More
